Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Nov 04, 2022 12:19pm
177 Views
Post# 35073471

RE:Could the volume here get any lower???????

RE:Could the volume here get any lower???????
I have resigned myself to the idea that it is not a big announcement. It is only 1 of many abstracts that are being presented by companies and even though we had amazing results with the first 3 patients it is stil an abstract and generally from my experience that does not trigger a sp increase or decrease until the release of the abstract and results. Will it be on just the first 3 paitients or more. Stay tuned for Monday and then hopefully the KOL meeting can expand on what we are seeing to help give a more clear picture of what we are seeing and the direction that onc might be taking....As much as we can speculate and have done many times in the past we all know that nothing is for sure with the company until it happens and we see it in print and even then that can change as for example with the Bracelet results which have now been pushed regardless of their reason. So hers's hoping that Monday actually for once is the start of something new and good for the company.
<< Previous
Bullboard Posts
Next >>